30 results for «1220»
30 results
Emerging indications for TAVI
18 May 2023 – From EuroPCR 2023
Consult this session if you want to learn about emergent indications of transcatheter treatment of aortic valve disease, to appreciate current gaps in the evidence base and hear about upcoming clinical trials, and to highlight new technologies that will address these treatment gaps.
Second time TAVI (TAV-in-TAV) - Not as simple as it looks
19 Nov 2023 – From PCR London Valves 2023
Although it is still rare, TAV-in-TAV is likely to become more frequent, as TAVI is increasingly implanted in younger patients. Harmonizing data in this area will therefore help to improve outcomes, the quality of which depends on site experience, bearing in mind that for the time...
Late-breaking trials on latest-generation aortic valves and dedicated transcatheter devices
20 Nov 2023 – From PCR London Valves 2023
Find out the outcomes of the main studies on the latest-generation valves and devices presented at PCR LV 2023 to better determine their benefits, performance and interest in the treatment of specific aortic pathologies: REACCESS-2 Study, ACURATE Neo2 PMCF post-market registry, OCEAN-TAVI registry, ShortCut Pivotal Study, and...
EuroPCR 2023 Hotlines/Late-Breaking Trials: focus on stent technology
17 May 2023 – From EuroPCR 2023
If you would like to learn more about the latest findings on stent techhnology, check-out this session in which speakers reviewed a series of recent trials, among them: 12-month primary endpoint outcomes of the BIOADAPTOR-RCT; Final 5-year results from the blinded ABSORB IV trial ; BIOMAG-I:...
Highlights in valvular heart disease research - The year in EuroIntervention
17 Nov 2025 – From PCR London Valves 2025
This session highlights the most impactful research in valvular heart disease published in EuroIntervention in 2025. It reviews pivotal studies such as the ASCoP registry on complex PCI in severe aortic stenosis, the LANDMARK trial comparing Myval THV to other valves, and the D-PACE scoring system...
TRISCEND, ACURATE neo2, the LuX-Valve System: Top Late-Breaking Trials from PCR London Vaves 2022
27 Nov 2022 – From PCR London Valves 2022
Discover a selection of PCR London Valves 2022 Late-Breaking Trial submissions and learn more about the latest evidence evidence concerning new transcatheter valve devices, emerging innovative devices as well as highlighted content from the EuroIntervention journal.
PCR Innovators Day - Innovations for valve treatment: new devices, new tools, new procedures
19 May 2022 – From EuroPCR 2022
Valvular heart disease is probably one of the most innovative areas in cardiovascular medicine at large: tremendous progress has been made both in terms of quality of life and mortality. Technology continues to evolve, as there are still many gaps to be filled, and it is...
Major Late-Breaking Trials from EuroPCR 2024
15 May 2024 – From EuroPCR 2024
This session presents the latest results from major late-breaking trials presented at EuroPCR 2024. It covers a one-month DAPT followed by 5-month ticagrelor monotherapy in acute coronary syndromes with DCB, the first TAVI vs. SAVR randomised trial in younger low-risk patients with severe tricuspid or bicuspid...
Asymptomatic severe aortic stenosis: Will these trials change my practice?
16 May 2024 – From EuroPCR 2024
This session, in collaboration with Partners in Learning, explores the emerging evidence on the use of transcatheter aortic valve implantation (TAVI) in patients with asymptomatic severe aortic stenosis. It covers data from registries and randomized controlled trials, the current guideline recommendations, and the potential impact of...
Predicting and managing TAVI conduction related disorders
20 May 2022 – From EuroPCR 2022
Get key learnings on conduction disorders after TAVI, the role of temporary pacing devices and different strategies to reduce permanent pacemaker implants to the minimum.
- ← previous
- 1
- 2
- next →